| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 684.9 | 581.7 | 579.6 |
| Other income | 19.1 | 0.5 | 1.8 |
| Total income | 703.9 | 582.2 | 581.4 |
| Profit before exceptional items & tax | 64.2 | 42.5 | 47.7 |
| Profit before tax | 64.2 | 42.5 | 47.7 |
| Net profit | 46.0 | 32.8 | 34.4 |
| Operating margin | 9.1% | 7.3% | 8.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +33.70% |
|---|---|
| Net profit, quarter on quarter | +40.20% |
| Revenue, year on year | +18.20% |
NSE results filing, NSE: ROSSARI. Figures extracted from the filing.
Rossari Biotech Ltd: key numbers
- Share price
- ₹444.20
- Market cap
- ₹2,461 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 16.3×Sector 37.5×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech achieved highest-ever Q4 revenue and EBITDA in FY26, driven by 15% volume-led annual revenue growth. Focus is shifting toward high-margin pharma and oil & gas segments.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.